Search
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigationalThe World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon. Tecovirimat is an antivira...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A InducersLandiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigationalLandiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine. It works to reduce the heart rate, myocardial contractility, and conduction v...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalSiponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over t...
Categories: P-glycoprotein substratesIbrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. It was developed out of...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalMirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound D...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalOzanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approve...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalGivinostat is a small molecule histone deacetylase (HDAC) inhibitor. It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lympho...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersDihydralazine
go.drugbank.com/drugs/DB12945ApprovedWithdrawnDihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors